Market Overview - On February 6, the A-share market experienced significant volatility, with the three major indices initially rebounding after a low open, but ultimately closing lower. The Shanghai Composite Index fell by 0.25% to 4065.58 points, the Shenzhen Component Index decreased by 0.33% to 13906.73 points, and the ChiNext Index dropped by 0.73% to 3236.46 points. The total market turnover was 2.16 trillion yuan, a decrease of 30.8 billion yuan from the previous trading day, with over 2700 stocks rising [1]. Sector Performance Strong Performing Sectors - The mining and oil sectors saw gains, with stocks like Tongyuan Petroleum and Zhun Oil Co. hitting the daily limit [1]. - The chemical sector, particularly fluorine chemicals, showed strength, with Tianji Co. reaching the daily limit. Lithium mining and battery sectors were also active, with stocks such as Kosen Technology and Dingsheng New Materials hitting the daily limit [1]. - The traditional Chinese medicine sector led the market, with stocks like Te Yi Pharmaceutical and Hansen Pharmaceutical hitting the daily limit, supported by a new development plan from the Ministry of Industry and Information Technology [2]. - The chemical sector experienced a collective surge, driven by rising prices of disperse dyes due to increased costs of upstream intermediates [2]. - The power equipment sector rebounded, with stocks like Jinkong Electric and Sanbian Technology hitting the daily limit, reflecting strong demand in the electricity industry [2]. Weak Performing Sectors - The consumer sector, including liquor, tourism, and retail, faced a collective decline, with stocks like Huangtai Liquor hitting the daily limit down [4]. - Real estate-related concepts declined, with Jingtou Development falling over 5%, amid mixed expectations for industry recovery [5]. - AI application concepts saw a downturn, with various AI-related stocks experiencing declines due to uncertainties in commercialization [6]. - The "中字头" (state-owned enterprises) and financial sectors also retreated, as investors sought safer investment strategies following previous gains [6]. Institutional Insights - CICC remains optimistic about the revaluation of Chinese assets, noting that there are no typical signs of a market top despite external pressures. The firm suggests maintaining an overweight position in Chinese stocks and looking for buying opportunities during market fluctuations [7]. - Tianfeng Securities highlights that market sentiment is fragile, with short-term investors cashing out as a primary reason for recent declines in gold prices. They anticipate a period of volatility for gold but expect it to rebound later in the year [7]. - Huachuang Securities predicts a strong recovery in the consumption market during the 2026 Spring Festival, driven by government-led initiatives and diverse promotional activities, which may exceed market expectations [8].

Market Overview - The market showed a recovery after an initial drop, with all three major indices closing in the green. The Shanghai Composite Index rose by 0.11%, the Shenzhen Component increased by 0.65%, and the ChiNext Index also gained 0.65% [1] Sector Performance - The chemical sector performed strongly, with stocks such as Cangzhou Dahua, Jinniu Chemical, Baichuan Co., and Baihehua hitting the daily limit [2] - The humanoid robot concept saw active performance, with stocks like Wuzhou Xinchun, Liancheng Precision, and Tianqi Co. reaching the daily limit [3] - The non-ferrous metals sector rebounded, with Hunan Gold and Xianglu Tungsten hitting the daily limit. The optical communication concept also saw a recovery, with Hangdian Co. achieving five consecutive daily limits [4] - The traditional Chinese medicine concept opened actively, with Te Yi Pharmaceutical hitting the daily limit [5] - Conversely, the consumer sector faced a collective decline, particularly in the liquor and tourism hotel sectors, with Huangtai Liquor and Dalian Shengya hitting the daily limit [6] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day [7] Individual Stock Highlights - Zhongji Xuchuang had the highest trading volume at over 11.5 billion yuan, followed closely by Xinyi Sheng at 11.3 billion yuan. Other notable stocks with high trading volumes included Ningde Times, Kweichow Moutai, Zijin Mining, and Xunwei Communication [8]

Market Overview - The US labor market data has intensified market pessimism, leading to a systematic sell-off in the tech sector, which has quickly spread globally, putting pressure on risk assets and entering a clear "de-leveraging resonance" phase [1] - The three major indices opened lower but later rebounded, with the Shanghai Composite Index rising by 0.11%, the Shenzhen Component Index by 0.65%, and the ChiNext Index by 0.65% at midday [1] - The trading volume in the Shanghai and Shenzhen markets was 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day [1] Geopolitical Impact - The situation in Iran remains tense, with the US State Department issuing a security warning for American citizens to leave Iran and prepare for self-reliant exit plans [2] - This geopolitical tension has led to a significant rebound in precious metals, with silver rising by 8% to $72.54 per ounce and gold increasing by over 1% to $4,826.9 per ounce [2] - International oil prices have also reversed course, with Brent crude rising from $66.9 to $67.5 [2] Sector Performance Chemical Sector - The chemical sector saw a broad rally, with stocks like Jinniu Chemical and Cangzhou Dahua hitting the daily limit [3][5] - The price of key intermediate materials for disperse dyes has surged from 25,000 yuan per ton to 38,000 yuan per ton, an increase of over 50% [5] Traditional Chinese Medicine - Stocks in the traditional Chinese medicine sector surged, with companies like Te Yi Pharmaceutical and Hansen Pharmaceutical hitting the daily limit [4] - The Ministry of Industry and Information Technology has issued a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030 [4] Power Equipment - The power equipment sector, including transformers, showed strong performance with stocks like Jinkong Electric and Sanbian Technology hitting the daily limit [6][7] Precious Metals - The precious metals sector has rebounded, with stocks like Hunan Gold and Xianglu Tungsten hitting the daily limit [8] - Silver prices increased by over 2% during the day, while gold prices returned above $4,800 [8] Institutional Insights - CICC maintains a positive outlook on the Chinese stock market, noting that there are no typical bull market top signals, and the funding environment remains ample with improving performance [9][10] - Tianfeng Securities highlights that market sentiment is fragile, with any news changes potentially triggering concentrated sell-offs by short-term investors [11] - Huachuang Securities anticipates a strong recovery in the consumption market during the 2026 Spring Festival, driven by government-led initiatives and diverse promotional activities [12]

Group 1 - The core viewpoint of the news is the collective rise of traditional Chinese medicine (TCM) stocks following the release of the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" by eight departments including the Ministry of Industry and Information Technology on February 5, 2026 [1] - The plan outlines six key tasks: improving raw material quality and supply stability, collaborative innovation, enhancing manufacturing capabilities, revitalizing the national medicine industry, and cultivating outstanding enterprises [1] - By 2030, the goal is to promote a number of innovative TCM drugs to be approved for market launch and to cultivate ten major varieties of traditional Chinese medicine [1] Group 2 - The upcoming release of the new essential drug catalog in 2026 is expected to include approximately 40% traditional Chinese medicine products, which will serve as a core policy driver for the growth of innovative TCM drugs [1] - The market is witnessing a resurgence of old TCM brands while new brands are gradually emerging, supported by the cleaning up of TCM licenses and resource allocation towards established brands [1] - As of February 6, 2026, the CSI Traditional Chinese Medicine Index (930641) rose by 2.45%, with significant increases in stocks such as Panlong Pharmaceutical (up 10.01%) and Longshen Rongfa (up 9.99%) [1] Group 3 - The CSI Traditional Chinese Medicine Index closely tracks the performance of listed companies involved in the production and sales of TCM [2] - As of January 30, 2026, the top ten weighted stocks in the CSI Traditional Chinese Medicine Index accounted for 55.13% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Group 1 - The core viewpoint is that multiple regions are implementing policies to support the traditional Chinese medicine (TCM) industry, with Zhejiang aiming to cultivate emerging industries like biomedicine, and Henan planning to develop 3-5 TCM companies with annual revenues exceeding 3 billion yuan [1] - The implementation of the "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" on January 27 establishes a unique evaluation system for TCM, combining traditional Chinese medicine theory, human experience, and clinical data, which emphasizes the development path for classic formulas and modified new drugs [1] - The regulations require TCM decoction pieces and formula granule manufacturers to establish a MAH (Marketing Authorization Holder) lifecycle responsibility system to ensure the safety, efficacy, and traceability of TCM [1] Group 2 - The CSI TCM Index (930641) rose by 0.92% as of February 5, 2026, with component stocks such as Darentang increasing by 3.67%, Pian Zai Huang by 3.62%, and Huaren Jiangzhong by 2.03% [1] - The TCM ETF (159647) closely tracks the CSI TCM Index and has shown a 0.92% increase, marking a three-day consecutive rise [1] - As of January 30, 2026, the top ten weighted stocks in the CSI TCM Index include Yunnan Baiyao, Pian Zai Huang, and Tong Ren Tang, collectively accounting for 55.13% of the index [2]

Group 1 - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 0.32%, with notable gains from companies such as Guangdong Wannianqing (301111) up 12.03%, and Panlong Pharmaceutical (002864) up 5.35% [1] - The demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to remain high, with a recovery in outsourcing demand anticipated due to the overseas interest rate cut cycle [1] - The adjustment of the basic drug catalog is expected to continue, presenting opportunities for the adjustment of traditional Chinese medicine varieties [1] Group 2 - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, reflecting the overall performance of the sector [2] - As of November 28, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.79% of the index, with notable companies including Yunnan Baiyao (000538) and Pianzaihuang (600436) [2]

Group 1 - The core viewpoint of the articles highlights the positive performance of the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 0.79% and specific stocks like Guangdong Wannianqing and Tailong Pharmaceutical showing significant gains [1] - The TCM sector is characterized as a defensive segment with both pharmaceutical and consumer attributes, showcasing a dividend advantage with the TCM ETF's 12-month dividend yield reaching 2.87% [1] - The peak flu season has arrived, with the H3N2 strain prevalent in Beijing, presenting opportunities for the TCM sector [1] Group 2 - The adjustment of the basic drug catalog is expected to continue, with a focus on opportunities for increasing TCM varieties [1] - The trend of declining prices for TCM materials is anticipated to lead to a recovery in gross margins, with optimism regarding the clearance of social inventories and innovation-driven growth [1] - The top ten weighted stocks in the Zhongzheng TCM Index account for 54.79% of the index, including major companies like Yunnan Baiyao and Tongrentang [2]

Core Viewpoint - The Chinese traditional medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by rising flu cases and the performance of key stocks in the industry [1][2]. Group 1: Market Performance - As of November 24, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.68%, with a one-year dividend yield of 3.18% [1]. - Key component stocks such as Jiaying Pharmaceutical (002198) increased by 4.48%, Zhongsheng Pharmaceutical (002317) by 2.86%, and others also showed positive growth [1]. - The Zhongzheng Traditional Chinese Medicine ETF (159647) increased by 0.40%, with the latest price at 1 yuan [1]. Group 2: Flu Trends and Impact - The National Influenza Center reported that the ILI% in southern hospitals was 5.5%, up from 4.6% the previous week, and higher than the same period in 2022 and 2024 [1]. - Northern hospitals reported an ILI% of 6.1%, also higher than the previous week and exceeding levels from the last three years [1][2]. - The rising flu positivity rates in both southern and northern regions are attributed to lower immunity against the H3N2 strain and an earlier onset of the flu season this year [2]. Group 3: Industry Outlook - The flu season for 2025-2026 is expected to peak higher than the previous year, leading to increased demand for respiratory infection-related products [2]. - The traditional Chinese medicine sector is anticipated to face short-term performance pressure but is expected to benefit from policies related to centralized procurement and basic medicine, as well as innovation-driven growth [2]. - The top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index account for 54.92% of the index, indicating a concentrated market structure [3].

Group 1 - The core viewpoint indicates a strong performance in the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 1.22% and individual stocks like Zhongsheng Pharmaceutical increasing by 9.98% [1] - The TCM ETF has shown a consistent upward trend, achieving an 8-day consecutive rise, with the latest price reported at 1.06 yuan [1] - The National Health Commission has projected a peak in influenza cases in China during mid-December to early January, which may positively impact the TCM market [1] Group 2 - CITIC Securities anticipates that the collection of traditional Chinese medicine will continue to expand, leading to increased brand concentration in the outpatient market [1] - The TCM industry is expected to reach a healthy inventory level by Q2 2025, following a period of destocking and sales efforts [1] - Continuous growth in R&D investment by TCM companies is highlighted as a key driver for future development, with a focus on innovative TCM contributing to stable growth [1]

Core Viewpoint - The Chinese medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by policy benefits and the rapid modernization of classic formulas into contemporary medicine [1][2]. Group 1: Market Performance - As of November 12, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.57%, with notable increases in constituent stocks such as Zhongsheng Pharmaceutical (002317) up by 10.02% and Panlong Pharmaceutical (002864) up by 10.00% [1]. - The Chinese Medicine ETF (159647) also saw a rise of 0.29%, marking its sixth consecutive increase, with the latest price reported at 1.05 yuan [1]. Group 2: Industry Trends - There is a continuous release of policy benefits, leading to an accelerated layout of classic formulas by Chinese medicine companies, with products like Loquat Lung Cleansing Granules and Warming Meridian Decoction being rapidly transformed into modern formulations [1]. - Guojin Securities identifies the main investment opportunities in the pharmaceutical sector for 2025 as the innovation drug theme and the reversal of challenges in the left-side sector, emphasizing the potential of dual/multi-antibody drugs and addressing unmet clinical needs in chronic disease medications [1]. Group 3: Index Composition - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, with the top ten weighted stocks accounting for 54.92% of the index as of October 31, 2025 [2].